Macquarie Group Ltd. boosted its position in West Pharmaceutical Services Inc. (NYSE:WST) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 110,290 shares of the medical instruments supplier’s stock after acquiring an additional 3,124 shares during the quarter. Macquarie Group Ltd. owned 0.15% of West Pharmaceutical Services worth $10,812,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of the stock. Berman Capital Advisors LLC purchased a new position in West Pharmaceutical Services in the 4th quarter valued at $27,000. Oregon Public Employees Retirement Fund increased its position in West Pharmaceutical Services by 9,703.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,836,204 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 2,807,272 shares in the last quarter. Contravisory Investment Management Inc. purchased a new stake in West Pharmaceutical Services during the 4th quarter worth about $121,000. Captrust Financial Advisors increased its position in West Pharmaceutical Services by 20.7% during the 4th quarter. Captrust Financial Advisors now owns 1,339 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 230 shares in the last quarter. Finally, Pendal Group Ltd grew its holdings in West Pharmaceutical Services by 34.5% in the 4th quarter. Pendal Group Ltd now owns 1,968 shares of the medical instruments supplier’s stock valued at $193,000 after buying an additional 505 shares during the period. 94.40% of the stock is currently owned by hedge funds and other institutional investors.
West Pharmaceutical Services stock traded up $1.42 during midday trading on Friday, hitting $123.68. 449,099 shares of the company were exchanged, compared to its average volume of 450,591. The firm has a market capitalization of $8.50 billion, a PE ratio of 44.01, a price-to-earnings-growth ratio of 3.65 and a beta of 1.25. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.40 and a current ratio of 3.15. West Pharmaceutical Services Inc. has a fifty-two week low of $84.91 and a fifty-two week high of $125.09.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Wednesday, April 17th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.49%. The ex-dividend date is Tuesday, April 16th. West Pharmaceutical Services’s dividend payout ratio is currently 21.35%.
WST has been the subject of several recent analyst reports. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Saturday, January 12th. William Blair began coverage on West Pharmaceutical Services in a report on Tuesday. They set an “outperform” rating and a $112.16 target price for the company.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading: Producer Price Index (PPI)
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.